2023
Impact of the COVID-19 pandemic on treatment approaches of multiple myeloma
Theprungsirikul P, Neparidze N. Impact of the COVID-19 pandemic on treatment approaches of multiple myeloma. Medical Research Archives 2023, 11 DOI: 10.18103/mra.v11i6.3912.Peer-Reviewed Original ResearchMultiple myelomaCOVID-19 infectionHematologic malignanciesTreatment approachesCOVID-19 pandemicAutologous stem cell transplantCoronavirus disease-19 (COVID-19) patientsImmune therapy approachesCellular immune dysfunctionRefractory multiple myelomaManagement of patientsStem cell transplantClinical practice guidelinesCommon hematologic malignancySevere clinical outcomesEarly pandemic periodCOVID-19Stable diseaseMajor comorbiditiesSteroid regimensCytotoxic chemotherapySupportive careImmune dysfunctionPrompt diagnosisTreatment initiation
2021
Outcomes Among Primary Refractory Multiple Myeloma Patients in the Era of Monoclonal Antibodies: The Yale Experience
Liu Y, Kywe B, Crawford L, Lora F, Bar N, Browning S, Gorshein E, Parker T, Neparidze N. Outcomes Among Primary Refractory Multiple Myeloma Patients in the Era of Monoclonal Antibodies: The Yale Experience. Blood 2021, 138: 1635. DOI: 10.1182/blood-2021-146619.Peer-Reviewed Original ResearchAutologous stem cell transplantMedian overall survivalInternational Staging System stage IIRefractory multiple myeloma patientsOverall survivalMultiple myeloma patientsMultiple myelomaInduction therapyPartial responsePrimary refractoryInduction regimenMyeloma patientsMonoclonal antibodiesPlasma cellsInternational Myeloma Working Group criteriaYale New Haven Health SystemStage IIHigh-risk cytogeneticsGood partial responseRetrospective cohort studyMajority of patientsMRD-negative statusMonoclonal antibody therapyStem cell transplantImportant prognostic value
2020
A Phase II Study of Isatuximab (SAR650984) (NSC-795145) for Patients with Previously Treated AL Amyloidosis (SWOG S1702; NCT#03499808)
Parker T, Rosenthal A, Sanchorawala V, Landau H, Campagnaro E, Kapoor P, Neparidze N, Hagen P, Sarosiek S, Scott E, Hoering A, Durie B, Usmani S, Orlowski R. A Phase II Study of Isatuximab (SAR650984) (NSC-795145) for Patients with Previously Treated AL Amyloidosis (SWOG S1702; NCT#03499808). Blood 2020, 136: 20-21. DOI: 10.1182/blood-2020-143180.Peer-Reviewed Original ResearchPhase II studyAL amyloidosisJanssen BiotechEligible patientsCardiac involvementII studyComplete responsePartial responseGrade IAnti-CD38 monoclonal antibody therapyCommon drug-related AEsECOG performance status 0Overall hematologic response rateAutologous stem cell transplantMonoclonal antibodiesAdvisory CommitteeDrug-related AEsHematologic response ratePerformance status 0Relapsed refractory myelomaGood partial responseHigh-dose therapyProgression-free survivalRefractory multiple myelomaStage III disease